ADMA Biologics vs Harmony Biosciences
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put ADMA Biologics and Harmony Biosciences side by side, using each oneβs latest annual report. Here is what stands out:
- Harmony Biosciences is the larger business, with $869M of revenue in fiscal 2025 against $510M for ADMA Biologics, about 1.7 times as much.
- Harmony Biosciences grew revenue faster (21.5%, against 19.6%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against 24.0%).
- Harmony Biosciences turned more of its sales into free cash flow (40.1% FCF margin, against 5.5%).
- Harmony Biosciences earned a higher return on the capital invested in it (48.9%, against 39.5%).
- Investors pay more for each dollar of ADMA Biologicsβs earnings: a P/E of 15.3x against 11.7x for Harmony Biosciences.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
ADMA Biologics
ADMA
5/10
5-year growthOperating marginNet marginReturn on equityShare count change
Harmony Biosciences
HRMY
4/10
Revenue growthGross marginFCF marginReturn on capital
Side by side
Best in the row
| Latest fiscal year | ADMA FY25 | HRMY FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | $2.1B |
| Revenue | $510M | $869M |
| Free cash flow | $27.8M | $348M |
| Net income | $147M | $159M |
| Growth | ||
| Revenue growth | 19.6% | 21.5% |
| 5-year growth | 64.6% | 40.3% |
| Share count change | 0.6% | 1.2% |
| Profitability | ||
| Gross margin | 57.4% | 77.2% |
| Operating margin | 37.5% | 24.0% |
| Net margin | 28.8% | 18.3% |
| FCF margin | 5.5% | 40.1% |
| Return on capital | 39.5% | 48.9% |
| Return on equity | 35.6% | 20.8% |
| Balance sheet | ||
| Net debt | β$15.5M | β$612M |
| Net debt / EBITDA | β0.1x | β |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | 11.7x |
| Piotroski F-score | 5 | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.